312 related articles for article (PubMed ID: 16038267)
1. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
[TBL] [Abstract][Full Text] [Related]
2. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
[TBL] [Abstract][Full Text] [Related]
3. Efficient ex vivo expansion of Valpha24+ NKT cells derived from G-CSF-mobilized blood cells.
Imataki O; Heike Y; Ishida T; Takaue Y; Ikarashi Y; Yoshida M; Wakasugi H; Kakizoe T
J Immunother; 2006; 29(3):320-7. PubMed ID: 16699375
[TBL] [Abstract][Full Text] [Related]
4. Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials.
Harada Y; Imataki O; Heike Y; Kawai H; Shimosaka A; Mori S; Kami M; Tanosaki R; Ikarashi Y; Iizuka A; Yoshida M; Wakasugi H; Saito S; Takaue Y; Takei M; Kakizoe T
J Immunother; 2005; 28(4):314-21. PubMed ID: 16000949
[TBL] [Abstract][Full Text] [Related]
5. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
[TBL] [Abstract][Full Text] [Related]
6. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
[TBL] [Abstract][Full Text] [Related]
7. Expansion of Valpha24(+)Vbeta11(+) NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes.
Okada H; Nagamura-Inoue T; Mori Y; Takahashi TA
Eur J Immunol; 2006 Jan; 36(1):236-44. PubMed ID: 16380959
[TBL] [Abstract][Full Text] [Related]
8. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells.
Marschner A; Rothenfusser S; Hornung V; Prell D; Krug A; Kerkmann M; Wellisch D; Poeck H; Greinacher A; Giese T; Endres S; Hartmann G
Eur J Immunol; 2005 Aug; 35(8):2347-57. PubMed ID: 16025562
[TBL] [Abstract][Full Text] [Related]
9. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
10. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases.
Kojo S; Adachi Y; Keino H; Taniguchi M; Sumida T
Arthritis Rheum; 2001 May; 44(5):1127-38. PubMed ID: 11352245
[TBL] [Abstract][Full Text] [Related]
11. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.
Imataki O; Heike Y; Makiyama H; Iizuka A; Ikarashi Y; Ishida T; Wakasugi H; Takaue Y
Cytotherapy; 2008; 10(5):497-506. PubMed ID: 18608348
[TBL] [Abstract][Full Text] [Related]
12. IL-21 enhances dendritic cell ability to induce interferon-gamma production by natural killer T cells.
Maeda M; Yanagawa Y; Iwabuchi K; Minami K; Nakamaru Y; Takagi D; Fukuda S; Onoé K
Immunobiology; 2007; 212(7):537-47. PubMed ID: 17678711
[TBL] [Abstract][Full Text] [Related]
13. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo.
Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T
Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792
[TBL] [Abstract][Full Text] [Related]
14. Natural killer T cells from interleukin-4-deficient mice are defective in early interferon-gamma production in response to alpha-galactosylceramide.
Togashi Y; Chamoto K; Wakita D; Tsutsumi N; Iwakura Y; Matsubara N; Kitamura H; Nishimura T
Cancer Sci; 2007 May; 98(5):721-5. PubMed ID: 17359285
[TBL] [Abstract][Full Text] [Related]
15. Alpha-galactosylceramide modulates the induction of indoleamine 2,3-dioxygenase in antigen presenting cells.
Fallarini S; Paoletti T; Panza L; Lombardi G
Biochem Pharmacol; 2008 Sep; 76(6):738-50. PubMed ID: 18671950
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
Osada T; Morse MA; Lyerly HK; Clay TM
Int Immunol; 2005 Sep; 17(9):1143-55. PubMed ID: 16027139
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.
Kunii N; Horiguchi S; Motohashi S; Yamamoto H; Ueno N; Yamamoto S; Sakurai D; Taniguchi M; Nakayama T; Okamoto Y
Cancer Sci; 2009 Jun; 100(6):1092-8. PubMed ID: 19302288
[TBL] [Abstract][Full Text] [Related]
18. H2-D(d)-mediated upregulation of interleukin-4 production by natural killer T-cell and dendritic cell interaction.
Mizuuchi K; Yanagawa Y; Iwabuchi K; Namba K; Kitaichi N; Ohno S; Onoé K
Immunology; 2008 May; 124(1):102-11. PubMed ID: 18194275
[TBL] [Abstract][Full Text] [Related]
19. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
